Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyAetna Stereotactic Radiosurgery Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0083

    Stereotactic Radiosurgery

    Customize your policy alerts

    Sign up for Aetna Policy 0083 alerts

    Get alerted when Policy 0083 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing when stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) are considered medically necessary for Aetna members; affects providers requesting coverage for these procedures and associated codes.

    Policy Summary
    PayerAetna
    PolicyStereotactic Radiosurgery
    Policy CodePolicy 0083
    Change TypeNo material change
    Effective DateNov 29, 1995
    Last ReviewFeb 8, 2023
    Next Review DateJan 25, 2024
    Key ActionObtain prior authorization and confirm medical necessity per eviCore Radiation Therapy Clinical Guidelines before requesting coverage for SRS/SBRT.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    eviCoreeviCore source
    <=4Max routine brain mets
    <=5SBRT fraction limit
    02/08/2023Last review
    ~75References cited

    Coverage Criteria for SRS / SBRT

    Medical Necessity (eviCore-guided)

    Covered when medical necessity criteria are met according to eviCore Healthcare Radiation Therapy Clinical Guidelines

    eviCore-based medical necessity: Procedures (SRS/SBRT) are considered medically necessary only when they meet the selection and medical necessity criteria established by the eviCore Radiation Therapy Clinical Guidelines referenced by Aetna.

    Providers must use eviCore criteria for individual case determination.

    Site-specific evidence summaries and implied clinical positioning

    Site-specific evidence summaries and implications for clinical use

    Cholangiocarcinoma (unresectable): SBRT produced outcomes comparable to conventionally fractionated chemoradiotherapy in a single-institution series but was associated with notable gastrointestinal toxicity related to duodenal dose exposure; careful patient selection and adherence to duodenal dose constraints are important.

    Kopek et al reported 45 Gy in 3 fractions with severe duodenal/pyloric ulceration in 6/27 patients.

    Policy Summary
    PayerAetna
    PolicyStereotactic Radiosurgery
    Policy CodePolicy 0083
    Change TypeNo material change
    Effective DateNov 29, 1995
    Last ReviewFeb 8, 2023
    Next Review DateJan 25, 2024
    Key ActionObtain prior authorization and confirm medical necessity per eviCore Radiation Therapy Clinical Guidelines before requesting coverage for SRS/SBRT.
    SourceLink
    On This Page
    Coverage Criteria for SRS / SBRTCoding and BillingProvider Actions, Prior Authorization, and DocumentationBackground and Evidence SummaryDefinitions and Key TermsPolicy Dates and Revision History
    Prostate cancer (localized): Phase I dose-escalation SBRT to 45–50 Gy in 5 fractions demonstrated acceptable short-term toxicity in small cohorts with 100% PSA control by nadir+2 definition and dose escalation to 50 Gy completed without dose-limiting toxicity.

    Boike et al: cohorts of 15 patients per dose level; median follow-up up to 30 months.

    Chordoma (mobile spine and sacrum): High-dose single-fraction SRS achieved high rates of radiographic control (95% stable or reduced tumor burden) with low treatment-related morbidity in a small series, though longer follow-up is needed to define long-term recurrence risk.

    Yamada et al: median single-fraction dose ~2400 cGy; median follow-up 24 months.

    Liver malignancies (HCC and metastases): SBRT/SABR offers promising local control and safety in selected patients (Child-Pugh A) and may be useful for inoperable or unresectable tumors, though major guideline versions cited did not list SRS as a standard option at the time.

    Van De Voorde et al and others report favorable outcomes; NCCN 2015 did not mention SRS as standard for hepatobiliary cancers.

    Pancreatic adenocarcinoma (locally advanced): Fractionated SBRT combined with gemcitabine produced acceptable acute and late GI toxicity and good local control and pain improvement in a phase II trial; systematic reviews report pooled analgesic reduction and pain response after SBRT.

    Herman et al: 33 Gy in 5 fractions, median OS 13.9 months, 1-year local control 78%; Buwenge et al pooled analgesic reduction ~71.5%.

    Operable early-stage NSCLC: Surgery (lobectomy with mediastinal lymph node sampling) remains the preferred standard for operable stage I–II NSCLC; SBRT shows promising outcomes for medically inoperable patients and comparative analyses suggest similar adjusted outcomes in select patients but randomized evidence remains limited.

    Howington et al and Zheng et al summarize guidelines and meta-analysis comparing SBRT and surgery.

    Indications with observational / systematic evidence

    Contexts with reported favorable outcomes in the cited literature (observational, systematic reviews, meta-analyses):

    Pancreatic adenocarcinoma: SBRT (fractionated) combined with chemotherapy showed reduced CA 19-9, median OS ~13.9 months, and 1-year local control ~78% in one reported cohort; systematic reviews show pooled pain response and analgesic reduction after SBRT for locally advanced pancreatic ductal adenocarcinoma.

    Evidence heterogeneous; NCCN did not list SRS as a therapeutic option (Version 2.2015).

    Epilepsy (medically refractory temporal lobe / mesial temporal lobe epilepsy): Radiosurgery has pooled seizure-free rates around 50% with delayed onset of effect (~14 months); surgical anterior temporal lobectomy provides higher early seizure freedom, so radiosurgery is an alternative for selected patients with trade-offs in timing and relapse on AED taper.

    Meta-analyses and reviews report lower seizure freedom compared with resection but possible neuropsychological advantages.

    Brain metastases with concurrent immune checkpoint inhibitors: Observational studies suggest concurrent SRS-SRT with immune checkpoint inhibitors may be associated with improved overall survival and local control versus non-concurrent therapy without increased acute neurologic or immune-related adverse events, but evidence is hypothesis-generating and requires validation.

    Concurrent defined as ICI within 2 weeks of SRS-SRT in one study; median OS reported 24.7 months for concurrent group.

    Repeat SRS for locally recurrent brain metastases: Pooled observational data report 1-year local control ~69%, 1-year OS ~49.7%, and an estimated radionecrosis rate of ~16.1%; dose escalation may improve local control.

    Singh et al systematic review and meta-analysis of repeat SRS.

    Oligometastatic colorectal cancer (liver and lung): SBRT reports 1-year local control ranges for liver (50%–100%) and lung (62%–92%) with low morbidity; BEDs reported vary widely across studies; data are encouraging but immature.

    Kobiela et al systematic review.

    Indication-level evidence summaries

    Findings summarizing clinical evidence by indication (no explicit 'covered when' rules in this excerpt):

    Glioblastoma (dural metastasis & newly diagnosed): Small case series and feasibility reports suggest SRS may produce radiographic responses in select dural GBM metastases and that fractionated approaches have been used experimentally for newly diagnosed GBM; evidence is limited and further trials are needed.

    Hintenlang et al: single-case dural metastasis treated with 20 Gy in 1 fraction showing near-complete resolution at 6 months.

    Oligometastatic colorectal cancer: Systematic reviews report 1- and 2-year local control ranges for liver (50–100% at 1 year; 32–91% at 2 years) and lung (62–92% at 1 year; 53–92% at 2 years); BED ranges widely; data are promising but not yet mature.

    Kobiela et al systematic review.

    Cerebral cavernous malformations: A systematic review of 30 cohort studies (n=1,576) found annual incidences after SRS of death 0.18%, intracerebral hemorrhage 2.40%, and persistent focal neurologic deficit 0.71%; outcomes appear comparable to non-SRS management but randomized trials are needed.

    Poorthuis et al systematic review.

    Incidental meningiomas: Meta-analysis demonstrated significantly higher tumor control with SRS versus observation over mean follow-up >3 years with acceptable morbidity; risk factors for progression include MRI T2 hyperintensity, larger initial diameter, and absence of calcification.

    Zhang and Zhang systematic review and meta-analysis.

    Pituitary adenomas (secretory): Meta-analysis shows high pooled tumor control rates for secretory pituitary adenomas but lower endocrine remission rates and a measurable risk of new hypopituitarism.

    Mathieu et al systematic review: tumor control rates high (eg, acromegaly 97%), endocrine remission lower (eg, acromegaly 44%).

    Small cell lung cancer (T1-2N0M0) treated with SABR: Meta-analysis of SABR for early node-negative SCLC reports 1-year local control ~97.3% and 1-year overall survival ~86.3% with limited high-grade toxicity reported.

    Safavi et al systematic review/meta-analysis.

    Vestibular schwannomas: Systematic reviews and a large multicenter retrospective cohort report high tumor control (≈89–94%) after SRS for Koos grade-IV tumors; facial nerve risk associates with higher margin dose and a recommended margin dose <13 Gy to reduce facial palsy risk.< 13 Gy

    Dumot et al and related analyses report tumor control ~94.1% and facial nerve risk with margin dose ≥13 Gy.

    Medial thalamotomy for intractable pain: Systematic review shows initial meaningful pain reduction in a proportion of patients with some persistent benefit but variable durability; adverse events are relatively uncommon.

    Aggregate initial meaningful pain reduction ~55%, persistent effect ~38%.

    Oligometastatic breast and renal cell cancers: Phase II SBRT for lung/liver oligometastases in breast cancer reported excellent tolerability with no grade 3–4 toxicities; retrospective SABR series in oligometastatic RCC suggest possible benefit when delivered early but are limited by small sample sizes.

    Franceschini et al (breast SBRT) and Ma et al (RCC retrospective SABR).

    Cranial Stereotactic Radiosurgery — Medically Necessary

    Covered when ANY of the following are met:

    Cranial SRS Indications: 1) Symptomatic, small (<3 cm) arterio-venous malformations, aneurysms, and benign intracranial tumors (eg, vestibular schwannomas, meningiomas, pituitary adenomas, hemangiomas) when unresectable due to deep location or the member is not a surgical candidate; 2) Trigeminal neuralgia refractory to conservative treatments; 3) Severe essential tremor not responsive to standard medical therapy; 4) Disabling tremor in Parkinson's disease meeting thalamotomy criteria but not a surgical candidate; 5) Brain malignancies (primary or metastatic) in members with good performance status (Karnofsky 80–100), controlled systemic disease, and no more than 4 metastatic lesions (treatment to additional lesions may require further justification); 6) Ocular melanomas not amenable to surgical excision or other conventional treatments.

    Cranial SRS with Cyberknife, Gamma Knife, or LINAC; treatment to additional brain lesions beyond 4 may need justification.

    Stereotactic Body Radiation Therapy — Medically Necessary

    SBRT is considered medically necessary for localized malignant conditions where high-precision high-dose radiotherapy is required, including:

    SBRT Indications: 1) Hepatocellular carcinoma in individuals with unresectable disease not suitable for transplantation or with local disease in patients unamenable to surgery due to comorbidities; 2) Organ-confined prostate cancer with Gleason score ≤8 and PSA <20; 3) Inoperable stage I or II non-small cell lung cancer; 4) Oligometastatic colorectal cancer (1–3 metastases to lung or liver) not amenable to surgery; 5) Inoperable primary spinal tumors with compression or intractable pain; 6) Recurrent metastatic disease in a previously irradiated area; 7) Recurrent localized head and neck cancer; 8) Metastatic lesions to the liver when sole site and not resectable/ablatable; 9) Metastatic disease to the lung when clinically appropriate on a case-by-case basis.

    All other clinical sites or indications are considered experimental and investigational but may be considered case-by-case.

    Fractionated Stereotactic Radiotherapy — Medically Necessary

    Fractionated stereotactic radiotherapy

    Fractionated Stereotactic Radiotherapy: Considered medically necessary when criteria for stereotactic radiosurgery are met and when fractionation is useful for tumors in hard-to-reach locations, unusual shapes, or in close proximity to vital structures (eg, optic nerve or hypothalamus) that cannot tolerate a single high-dose fraction.

    Fractionation employed when single-fraction SRS is not tolerable due to adjacent critical structures.

    Proton Beam Radiosurgery — Cross-reference

    Stereotactic proton beam radiosurgery

    Proton Beam Reference: See separate policy CPB 0270 for stereotactic proton beam and neutron beam radiotherapy.

    Cross-reference to CPB 0270.

    Experimental and Investigational Indications — Not Medically Necessary

    Considered experimental and investigational for indications where effectiveness not established, including (not all-inclusive):

    Experimental/Investigational Indications: Cluster headaches; epilepsy (except when associated with treatment of AV malformations or brain tumors); mammographic microcalcification; and all other clinical sites or indications not listed as medically necessary.

    Effectiveness for these indications has not been established; treatments considered experimental/investigational.

    The policy lists specific ICD-10 codes not covered for the indications addressed in this Clinical Policy Bulletin. These include codes for epilepsy and recurrent seizures (G40.001–G40.919), cluster headache and trigeminal autonomic cephalgias (G44.001–G44.099), post-traumatic seizures (R56.1), unspecified convulsions (R56.9), and mammographic microcalcification (R92.0). Providers should not expect coverage for SRS/SBRT when those diagnoses are the stated indication under this CPB.

    The document cites guideline commentary noting that in certain disease sites NCCN and specialty panels did not endorse SBRT/SRS as a substitute for established therapies. For example, the American College of Radiology/ACR Appropriateness Panel on early-stage cervical cancer stated that although SBRT has preliminary data in other sites, SBRT should not be considered a substitute for brachytherapy because of target motion and the proven outcomes of brachytherapy.

    The policy notes that the NCCN Hepatobiliary and Pancreatic guidelines (Version 2.2015) did not list stereotactic radiosurgery as a therapeutic option. Specifically, the Hepatobiliary guideline did not mention SRS, and the Pancreatic adenocarcinoma guideline likewise did not mention SRS as a therapeutic option in the cited guideline version, implying lack of guideline endorsement at that time.

    An UpToDate review on vascular malformations states that clinicians should not use stereotactic radiosurgery as the primary treatment for cerebral cavernous malformations. SRS may be considered for surgically inaccessible lesions, but high complication rates in published series and sparse long-term safety data have discouraged routine primary use.

    Any clinical site or indication not explicitly listed in the policy’s medically necessary sections is treated as experimental and investigational. The CPB gives examples (e.g., cluster headaches, epilepsy except when associated with AV malformations or brain tumors, and mammographic microcalcifications) and states that all other non-listed indications will be considered on a case-by-case basis and lack established effectiveness.

    This Clinical Policy Bulletin is a summary developed to assist in administering plan benefits and does not constitute a contract or a complete listing of plan-specific exclusions. Providers remain responsible for confirming individual plan coverage and any specific exclusions not detailed in this CPB.

    The policy identifies the use of SRS/SBRT for certain listed ICD-10 indications (for example, epilepsy/seizures, cluster headaches/TACs, and mammographic microcalcifications) as not supported for coverage under this CPB. These diagnoses are explicitly included among the ICD-10 codes described as not covered for the indications listed.

    For operable patients where surgery is the established standard of care (for example, operable stage I–II non–small cell lung cancer), the policy states that surgical resection (lobectomy with mediastinal lymph node sampling) remains the preferred standard; SBRT is positioned primarily for medically inoperable patients or those refusing surgery rather than as a first-line replacement.

    Within the provided excerpts there are no explicit ‘not medically necessary’ statements for every indication; however, referenced guidance (e.g., UpToDate on cavernous malformations) advises against using primary SRS for cerebral cavernous malformations in general, reflecting cautious clinical positioning rather than a blanket policy exclusion.

    The CPB identifies stereotactic radiosurgery as not supported for indications including cluster headaches, epilepsy (except when treating associated AV malformations or brain tumors), and mammographic microcalcifications. These examples are included in the list of indications considered experimental and investigational.

    In the portions of the document provided there are no additional explicit ‘not medically necessary’ criteria beyond the listed ICD-10 exclusions and investigational indications. The CPB and accompanying Aetna notes emphasize that the bulletin is a partial summary and specific not-medically-necessary determinations may depend on plan-specific rules and the eviCore guideline-based medical necessity process.

    Coding and Billing

    Covered CPT Codes (when selection criteria met)CPTCovered
    20660Application of cranial tongs, caliper, or stereotactic frame, including removal (separate procedure).
    32701Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT), (photon or particle beam), entire course of treatment.
    61796Stereotactic radiosurgery (particle beam, gamma ray or linear accelerator); 1 simple cranial lesion.
    61797Each additional cranial lesion, simple (List separately in addition to code for primary procedure).
    617981 complex cranial lesion.
    61799Each additional cranial lesion, complex (List separately in addition to code for primary procedure).
    61800Application of stereotactic headframe for stereotactic radiosurgery (List separately in addition to code for primary procedure).
    63620Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion.
    63621Each additional spinal lesion (List separately in addition to code for primary procedure).
    77371Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based.
    1–10 of 14
    1/2
    Covered HCPCS Codes (when selection criteria met)HCPCSCovered
    C9795Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions.
    G0339Image guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session, or first session of fractionated treatment.
    G0340Image guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum 5 sessions per course of treatment.
    Other HCPCS Related CodesHCPCS
    A4648Tissue marker, implantable, any type, each.
    A4650Implantable radiation dosimeter, each.
    ICD-10 Codes Covered (when selection criteria met)ICD-10Covered
    C00-C96Malignant neoplasms.
    D18.00-D18.09Hemangioma [hemangioblastoma].
    D33.0-D33.2Benign neoplasm of brain.
    G20Parkinson's disease.
    G21.0-G21.9Secondary parkinsonism.
    G25.0Essential tremor.
    G50.0Trigeminal neuralgia.
    I67.1Cerebral aneurysm, nonruptured.
    Q28.2-Q28.3Other congenital malformations of circulatory system.
    ICD-10 Codes Not Covered for Indications ListedICD-10Not Covered
    G40.001-G40.919Epilepsy and recurrent seizures (ICD-10 codes listed as not covered for indications in the CPB).
    G44.001-G44.099Cluster headache and trigeminal autonomic cephalgias (TAC) (listed as not covered).
    R56.1Post traumatic seizures (listed as not covered).
    R56.9Unspecified convulsions (listed as not covered).
    R92.0Mammographic microcalcification found on diagnostic imaging of breast (listed as not covered).
    No explicit CPT/HCPCS/ICD codes in this excerptmixed
    exact codeexact description from document
    No code lists in this partmixed
    No codes listed
    SBRT fraction limit — coding-based constraint
    Policy limitEntire SBRT treatment course not to exceed 5 fractions per procedure coding (CPT 77373; HCPCS G0340; HCPCS C9795)
    Relevant CPT77373 — Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions; entire course not to exceed 5 fractions
    Relevant HCPCS (robotic LINAC fractionation)G0340 — Image guided robotic LINAC-based stereotactic radiosurgery, fractionated treatment, per session, second through fifth sessions (maximum 5 sessions per course)
    Relevant HCPCS (advanced SBRT delivery)C9795 — SBRT treatment delivery per fraction, including image guidance and PET-based real-time adjustments; entire course not to exceed 5 fractions
    Koos grade‑IV vestibular schwannoma — margin dose recommendation
    Recommended maximum margin doseKeep prescription/margin dose less than 13 Gy for Koos grade‑IV vestibular schwannomas to reduce facial nerve palsy risk
    Observed associationFacial nerve deterioration was associated with margin doses ≥13 Gy (p = 0.03)
    Clinical implicationUse lower margin doses (<13 Gy) when feasible to decrease post‑SRS facial palsy incidence
    Median tumor size in SCLC SABR studies
    Median tumor size reportedMedian tumor size in analyzed SCLC SABR studies was 24 mm
    ContextMeta-analysis of SABR for T1-2N0M0 SCLC reported median tumor size 24 mm (range 19–29 mm) and median follow-up ~19.5 months
    ImplicationSABR evidence in early-stage SCLC largely derives from tumors with median diameter around 24 mm

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    eviCore guideline-based prior authorization

    Prior authorization/medical necessity determinations must adhere to eviCore Radiation Therapy Clinical Guidelines. Coverage is contingent on meeting eviCore medical necessity criteria; failure to meet these criteria may result in non-coverage. eviCore guidelines are reviewed annually and may change; draft guidelines are posted 90 days prior to implementation.

    • Refer to eviCore Radiation Therapy Clinical Guidelines for medical necessity determinations.
    • Coverage contingent on meeting eviCore criteria; non-coverage possible if criteria not met.
    Documentation Required

    Site-specific selection confirmation recommended

    Site-specific selection and eligibility features described in trials and reviews should be confirmed when proposing SRS/SBRT for a given anatomic site. Consider trial-defined limits (lesion counts, size limits, resectability) and specialty guideline recommendations when selecting patients.

    • Confirm site-specific eligibility criteria from relevant trials and guidelines (lesion count, size, resectability, performance status).
    • For additional lesions beyond typical limits (eg, >4 brain metastases) provide further clinical justification.
    Prior Authorization

    PA recommended for SRS with concurrent ICI and repeat SRS

    Prior authorization is recommended when SRS/SRT is planned concurrently with immune checkpoint inhibitors (ICI) or when repeat SRS is requested for locally recurrent brain metastases. These scenarios have evolving evidence and may require case review and documentation of rationale and timing relative to ICI.

    • PA recommended for SRS/SRT concurrent with ICI (concurrent defined in studies as within ~2 weeks).
    • PA recommended for repeat SRS for locally recurrent brain metastases; include prior treatment history and interval since prior RT.
    Prior Authorization

    Prior authorization: study-based inclusion criteria

    Prior authorization requests that reflect study-based inclusion criteria should document lesion counts, size limits, performance status, systemic disease control, and prior treatments when applicable. Trial eligibility (for example: ≤4 brain metastases, lesion size thresholds, Karnofsky score 80–100, ECOG 0–2) should be provided when using study-based rationale.

    • Include trial-based inclusion criteria when citing studies (lesion counts, size limits, Gleason/PSA limits for prostate trials, ECOG/Karnofsky performance status).
    • If request is based on a specific clinical trial, cite the trial and show the member meets key inclusion criteria.
    Prior Authorization

    Prior authorization requirements

    Prior authorization requirements: submit relevant CPT/HCPCS and ICD-10 codes and supportive clinical documentation. Authorization may be required when requests fall outside routine, clearly specified coverage criteria (eg, non-standard sites, additional lesions, concurrent systemic therapies).

    • Submit CPT/HCPCS/ICD-10 codes listed in the policy when requesting coverage.
    • PA likely when request is for indications considered experimental/investigational or outside listed medically necessary criteria.
    Note

    Evidence gaps may affect coverage

    Evidence gaps noted by AHRQ and guideline reviews may affect coverage decisions. Many SBRT/SRS indications lack randomized comparative trials; some recommendations are based on level III (retrospective) evidence or single-arm studies. When evidence is limited, case-by-case review and additional documentation may be required.

    • AHRQ technical brief identifies gaps and the need for randomized or concurrent-control studies.
    • Lack of high-level evidence for many indications may prompt individualized coverage review.
    Note

    Evidence limitations may affect coverage decisions

    Evidence limitations (retrospective databases, single-arm series) can introduce confounders that affect interpretation and coverage decisions. When basing requests on such evidence, include rationale addressing limitations (eg, selection bias, unmeasured confounders, differences in systemic therapy availability).

    • Retrospective analyses (eg, NCDB studies) may lack details on systemic therapy and cause of death—address these limitations in requests.
    • When relying on level III evidence, provide clinical justification and any additional supporting literature.
    Step Therapy

    No step therapy mandates specified

    No mandatory step therapy (sequencing) requirements are specified in this policy excerpt. Standard surgical or other established treatment options should be considered prior to radiosurgical approaches when clinically appropriate (for example, surgery is preferred for operable stage I–II NSCLC).

    • No step therapy mandates specified in this CPB.
    • Consider conventional surgical options before radiosurgery when surgery is standard of care (eg, operable NSCLC).
    Billing Rule

    Coding must be submitted

    Providers should submit relevant CPT, HCPCS, and ICD-10 codes as listed in the policy when requesting coverage, along with all supporting clinical documentation. Incomplete coding or missing documentation may delay PA determinations.

    • Include CPT/HCPCS/ICD-10 codes from the policy in the PA request.
    • Provide complete clinical documentation to support medical necessity.
    Documentation Required

    Suggested supporting documentation

    Suggested supporting documentation: clinical indication, prior treatments, imaging (simulation and planning), target volumes, lesion counts and sizes, performance status, systemic disease status, and relevant trial citations or guideline references.

    • Imaging used in trials: 4D-CT and FDG-PET/CT for simulation and target definition—attach images/reports when available.
    • Document lesion counts, maximum diameters, margins, and motion-management measures (eg, rectal balloon for prostate SBRT) as applicable.
    Documentation Required

    Supporting documentation for non-standard or evolving indications

    For non-standard or evolving indications, submit clinical rationale and relevant literature to support the request. Case-by-case review will consider the balance of potential benefit and available evidence.

    • Provide peer-reviewed literature or trial data when requesting coverage for experimental/less-established sites.
    • Explain why conventional therapies are not appropriate or feasible for the member.
    Documentation Required

    Imaging and trial inclusion documentation

    Imaging and trial inclusion documentation: trials commonly used 4D-CT and FDG-PET/CT for simulation and target delineation; document imaging modality, fusion details, and target margins in the PA request.

    • Attach simulation and planning imaging reports (eg, 4D-CT, FDG-PET/CT) and note fusion methods.
    • Specify target definitions and margins used for planning as reported in supporting trials.
    Documentation Required

    Clinical justification and performance status

    Clinical justification should include performance status (eg, Karnofsky 80–100 or ECOG 0–2), evidence of controlled systemic disease when required, and prior therapy history. For brain metastases, limit to no more than 4 lesions unless further justification is provided.

    • Document Karnofsky or ECOG performance status and systemic disease control.
    • Provide prior treatment history and rationale for SRS/SBRT versus alternatives.
    Note

    Not specified in these chunks

    Not all provider-action items are specified in the extracted chunks; where a required operational detail is not listed (eg, explicit PA code lists or denial triggers), follow the general instruction to submit comprehensive clinical documentation and consult eviCore or payer administrative resources for specific PA submission rules.

    • If a specific authorization rule or code requirement is not detailed here, contact eviCore/Aetna for submission requirements.
    • This CPB is a summary and does not replace payer or eviCore operational procedures.
    Documentation Required

    Surgery preferred for operable NSCLC

    Surgical resection remains the preferred standard for operable stage I–II non-small-cell lung cancer (NSCLC); SBRT is an alternative when patients are medically inoperable or refuse surgery. Ensure multidisciplinary assessment and documentation when selecting SBRT over surgery.

    • Document multidisciplinary assessment and reasons surgery is not appropriate if SBRT is requested for operable-stage disease.
    • If citing comparative evidence, acknowledge limitations and reference trials or meta-analyses.
    Documentation Required

    Consider standard surgical options before radiosurgery

    Consider standard surgical or other established treatments prior to radiosurgery where applicable. Radiosurgical approaches should be selected when surgery is not feasible, contraindicated, or when evidence supports comparable outcomes in the specific clinical context.

    • Prioritize conventional surgical options when they are standard of care.
    • Provide documentation of contraindications to surgery when requesting radiosurgery instead.
    Note

    Policy history and administrative note

    Policy history and administrative notes: this Clinical Policy Bulletin contains a partial, general description of benefits and does not constitute a contract. The policy effective date is 1995-11-29; last review noted 02/08/2023 with next review 01/25/2024. For operational questions, consult payer resources.

    • Effective date: 1995-11-29. Last review: 02/08/2023. Next review: 01/25/2024.
    • CPB is informational and not a substitute for contractual benefit language.

    Background and Evidence Summary

    Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) deliver highly conformal, high-dose ionizing beams focused on a defined target while minimizing dose to adjacent normal tissues. Successful delivery relies on rigid or reproducible immobilization, high-resolution imaging for target delineation and planning (CT and MRI fusion, 4‑D CT for moving targets), and image guidance during treatment. Fractionation schemes vary by indication from single-fraction SRS to multi‑fraction SBRT or fractionated stereotactic radiotherapy when proximity to critical structures necessitates dose spreading.

    Site-specific evidence summaries (supporting)

    Site-specific evidence summaries referenced in background section as relevant to clinical positioning

    Cholangiocarcinoma (unresectable): Single-institution series of linac-based SBRT (45 Gy in 3 fractions) for unresectable cholangiocarcinoma reported median PFS 6.7 months and OS 10.6 months but high rates of severe duodenal/pyloric ulceration and duodenal stenosis in some patients, with toxicity related to duodenal dose exposure.

    Kopek et al (27 patients); careful patient selection and duodenal constraints advised.

    Prostate cancer (localized): Phase I trial of SBRT dose escalation (45–50 Gy in 5 fractions) in selected low- to intermediate-risk patients showed acceptable short-term GI/GU toxicity and 100% PSA control by nadir+2 in small cohorts.

    Boike et al: groups of 15 patients with median follow-up up to 30 months.

    Chordoma (mobile spine and sacrum): Single-fraction high-dose SRS (median 2400 cGy) in 24 patients demonstrated 95% stable or reduced tumor burden at median follow-up 24 months with limited complications, suggesting good short-term tumor control.

    Yamada et al series; longer follow-up required.

    Pancreatic adenocarcinoma: Phase II multi-institutional trial of gemcitabine plus fractionated SBRT (33 Gy in 5 fractions) reported median OS 13.9 months, 1-year freedom from local progression 78%, and acceptable acute and late GI toxicity; systematic reviews report pooled analgesic reduction after SBRT.

    Herman et al and Buwenge et al findings.

    Operable early-stage NSCLC: Guidelines state surgical resection remains preferred for operable stage I–II NSCLC; meta-analyses adjusting for operability show similar OS/DFS between SBRT and surgery in select patients but randomized trials are needed.

    Howington et al guideline and Zheng et al meta-analysis.

    Indications with observational / systematic evidence (supporting)

    Indications with observational / systematic evidence summarized here

    Pancreatic adenocarcinoma: Fractionated SBRT plus chemotherapy associated with meaningful local control, pain reduction, and median OS ~13.9 months in reported series; systematic reviews show pooled analgesic reduction and pain response but heterogeneity across studies.

    Herman et al and Buwenge et al; evidence heterogeneous.

    Repeat SRS for recurrent brain metastases: Meta-analysis of repeat SRS shows estimated 1-year local control ~69%, 1-year OS ~49.7%, and radionecrosis rate ~16.1%; dose escalation may increase local control.

    Singh et al and related pooled analyses.

    Concurrent SRS with immune checkpoint inhibitors: Observational cohorts suggest concurrent SRS and ICI (defined as ICI within 2 weeks of SRS in one study) may be associated with improved median OS (eg, 24.7 months) and no increase in acute neurologic or immune-related adverse events, but results are hypothesis-generating.

    Chen et al retrospective cohort.

    Guideline bodies and systematic reviewers have identified evidence gaps and the need for comparative studies — including randomized or concurrent-control trials — to fully establish comparative effectiveness of SBRT/SRS versus standard treatments. These limitations and the predominance of observational data in many indications may influence coverage determinations and underscore the role of eviCore guideline-based prior authorization for individual medical necessity assessments.

    Definitions and Key Terms

    Stereotactic Radiosurgery (SRS) — definition and features
    DefinitionStereotactic Radiosurgery (SRS) is a procedure that delivers a highly focused, high‑dose ionizing beam (single or few sessions) to a cranial target with immobilization and imaging guidance to minimize dose to adjacent structures.
    Procedural featuresRequires precise immobilization (frame or frameless systems) and imaging guidance (angiography, CT, MRI) to ensure accurate targeting and sparing of adjacent tissue.
    Typical indicationsUsed for intracranial lesions including AVMs, small benign tumors, selected primary and metastatic brain tumors, and functional disorders when surgery is not appropriate.
    Stereotactic Body Radiation Therapy (SBRT) — definition and features
    DefinitionStereotactic Body Radiation Therapy (SBRT) is the application of stereotactic radiation principles to extracranial sites using body frames or frameless systems with skeletal landmarks or implanted fiducial markers; can be delivered in single or multiple fractions (commonly up to 5 fractions).
    Procedural featuresEmploys immobilization (body frame or frameless techniques), image guidance, and high conformality to deliver ablative doses to extracranial targets while sparing adjacent organs.
    Fractionation noteHypo‑fractionated regimens commonly delivered over 5–8 treatment days; coding and policy commonly limit entire SBRT courses to a maximum of 5 fractions for certain codes.
    Fractionated Stereotactic Radiotherapy (FSRT) — definition
    DefinitionFractionated Stereotactic Radiotherapy (FSRT) involves multiple low‑dose stereotactic treatments used for tumors in difficult locations or adjacent to vital structures that cannot tolerate a single high‑dose fraction.
    Typical useOften used for lesions close to optic apparatus, hypothalamus, or in pediatric patients to reduce toxicity while maintaining conformal dose delivery.
    ImmobilizationMay require customized immobilization (e.g., fiberglass helmet) and daily stereotactic imaging for accurate fractionated delivery.
    SBRT / SABR — alternate name and definition
    Alternative nameSBRT is also called Stereotactic Ablative Radiotherapy (SABR)
    Definition (alternate phrasing)Delivery of high, ablative doses of radiation to extracranial targets in a small number of highly conformal fractions with image guidance.
    Clinical noteUsed for localized malignant conditions where high‑precision, high‑dose radiotherapy is required and conventional surgery is not feasible or appropriate.
    SRS — short definition
    Short definitionSRS: highly focused high‑dose ionizing beam delivered in a single or few sessions to an intracranial target with immobilization and imaging guidance.
    Key pointDesigned to obliterate the target while sparing adjacent structures via precise beam intersection and immobilization.
    ModalitiesCan be delivered with Gamma Knife (Cobalt‑60), LINAC, or robotic systems depending on clinical context.
    SBRT — short definition
    Short definitionSBRT: stereotactic radiation applied to extracranial sites using body frames or frameless systems and image guidance, often delivered in up to 5 fractions.
    Key pointProvides ablative doses with high conformality to spare nearby organs at risk.
    Common sitesLung, liver, spine, pancreas, and selected oligometastatic lesions.
    SRS/RS — radiosurgery notation
    NotationSRS/RS is used interchangeably to denote stereotactic radiosurgery or radiosurgery techniques (e.g., Gamma Knife, LINAC-based systems)
    ContextTerm typically applied to highly focused intracranial radiation procedures for tumors and functional targets.
    Clinical implicationNaming may vary by device or technique but refers to stereotactic high‑dose intracranial treatment.
    Glioblastoma multiforme (GBM) — definition and context
    Definition/contextGlioblastoma multiforme (GBM) is a primary, diffusely infiltrative high‑grade brain neoplasm with poor prognosis; standard care includes maximal resection, postoperative radiotherapy, and temozolomide.
    SRS contextSRS has been reported in small case series for dural GBM metastases or selected scenarios but its role remains undefined and evidence is limited.
    Clinical implicationUse of SRS in GBM is investigational and should be considered case‑by‑case pending further evidence.
    Oligometastatic disease — definition and example
    Definition (study context)Oligometastatic disease refers to patients with a limited number of metastases (examples in SBRT trials: up to 5 lung/liver lesions) and controlled or stable extra‑pulmonary disease.
    Trial examplePhase II SBRT trial allowed up to 5 lung and/or liver lesions with metastatic disease confined to lungs and liver or stable/responding extra‑hepatic/extra‑pulmonary disease.
    Clinical implicationSBRT may be considered for oligometastatic patients when lesions are limited in number and systemic disease is controlled or responding to therapy.
    Good performance status — Karnofsky 80–100
    Good performance statusKarnofsky Performance Scale score between 80 and 100 (able to perform normal activity with effort) is required for certain SRS indications.
    UsageApplied as an eligibility requirement for SRS treatment of brain malignancies in policy guidance.
    DocumentationProviders should document Karnofsky score and systemic disease control when requesting SRS for brain malignancies.
    Oligometastatic disease (example) — referenced limits
    Example limitsOligometastatic colorectal cancer example: 1–3 metastases to lung or liver cited as appropriate for SBRT when not amenable to surgery.
    Policy wordingSBRT indicated for oligometastatic colorectal cancer (1 to 3 metastases to the lung or liver) not amenable to surgery.
    Clinical implicationSBRT selection for oligometastatic disease should consider lesion count and resectability.
    Clinical Policy Bulletin — administrative definition and disclaimer
    Administrative definitionClinical Policy Bulletin: Aetna document developed to assist in administering plan benefits; not an offer of coverage or medical advice.
    Legal noteThis CPB contains only a partial, general description of plan or program benefits and does not constitute a contract.
    Provider responsibilityTreating providers are solely responsible for medical advice and treatment of members; CPB may be updated and is subject to change.

    Policy Dates and Revision History

    Oligometastatic colorectal cancer: Systematic review reports high 1-year local control for liver and lung metastases treated with SBRT and low morbidity, though further studies are needed.

    Kobiela et al.